HealthDay News — According to a study published in the Journal of the American Medical Association, 2 doses of the human papillomavirus (HPV) vaccine, rather than 3, can effectively protect younger teens against the virus.
The study was one of a number evaluated by the US Centers for Disease Control and Prevention earlier this year, which led to the CDC’s revised guidelines in October.
The research included 1518 young people, aged 9 to 26, who were vaccinated against HPV at 52 sites in 15 countries. Researchers administered 2 doses of HPV vaccine to teens aged 9 to 14, and 3 doses of the vaccine to older teens and young women.
The researchers found that girls and boys in the younger age group achieved the same immunity with 2 doses 6 to 12 months apart as older teens and young women did on a 3-dose regimen over 6 months.
“With a simplified schedule and lower cost, it can be assumed [there would be] both higher coverage and improved compliance,” lead author Ole-Erik Iversen, MD, PhD, from the University of Bergen in Norway, told HealthDay.
The study was funded by Merck.
Iversen O, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016. doi:10.1001/jama.2016.17615. [Epub ahead of print]
Markowitz LE, Meites E, Unger ER. Two vs Three Doses of Human Papillomavirus VaccineNew Policy for the Second Decade of the Vaccination Program. JAMA. 2016. doi:10.1001/jama.2016.16393. [Epub ahead of print]